Fig. 1: Schematic diagram of the design of SARS-CoV-2 Mpro inhibitors.

a, The classical one-pot Ugi four-component reaction (Ugi-4CR). b, Fragments R, R1, R2 and R3 in Ugi-4CR occupy the S1′, S1, S2 and S4 pockets of Mpro, respectively.

a, The classical one-pot Ugi four-component reaction (Ugi-4CR). b, Fragments R, R1, R2 and R3 in Ugi-4CR occupy the S1′, S1, S2 and S4 pockets of Mpro, respectively.